Tafamidis: The First Breakthrough Therapy for the treatment of ATTR-CM

Speciality: Cardiology

Description:

A warm welcome to all the medical professionals in this interesting session on the use of Tafamidis as the first breakthrough therapy in managing ATTR-CM. We have Prof. Fabian Knebel, Dr. Jamshed Dalal, Dr. JC Mohan, Dr. VK Chopra, and Dr. C Narsimhan as the respective speakers in this session.

Transthyretin amyloid cardiomyopathy is a rare, life-threatening heart disease which is characterized by building up of abnormal deposits of amyloid in the heart as a result of misfolding of the transthyretin protein. It is defined by restrictive cardiomyopathy and progressive heart failure.

Transthyretin amyloid cardiomyopathy (ATTR-CM) is an underdiagnosed heart disease and can be a potentially fatal disease. It generally affects the left ventricle of the heart.

Tafamidis is a medication usually sold under the brand names of Vyndaqel and Vyndamax to delay the disease progression in adults with transthyretin amyloidosis. It is an oral medication for treating cardiomyopathy and peripheral neuropathy. It works as a transthyretin stabilizer thereby limiting the progression of the disease.

Therefore, listen to the webinar, grab the knowledge that is shared and follow HiDoc for more such interesting webinar sessions.
 

See More Webinars @ Hidoc Webinars